Pneumology - Original Articles Open access

Latent tuberculosis infection in patients with rheumatoid arthritis receiving conventional synthetic disease-modifying antirheumatic drugs: a prospective cross-sectional study from the Himalayas

Authors

Published
16 November 2026
Issue
Early Access
Section
Pneumology - Original Articles

Abstract

Rheumatoid arthritis (RA) and its treatments increase the susceptibility to tuberculosis (TB), mainly in TB-endemic settings. Latent TB infection (LTBI) screening is mandatory before biologic disease-modifying antirheumatic drugs. However, data on LTBI among RA patients receiving conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), particularly from north India, are limited. Tuberculin skin testing (TST) may underestimate LTBI in patients with RA because of impaired cell-mediated immunity and reduced delayed-type hypersensitivity responses.

In this prospective cross-sectional study, to exclude active TB, 146 consecutive adults with RA (ACR/EULAR 2010 criteria) receiving csDMARDs for ≥3 months underwent Mantoux TST (2 tuberculin units purified protein derivative; reading at 48-72 hours) and chest radiography . Using the conventional cut-off (≥10 mm), LTBI prevalence was 8.2% [12/146; 95% confidence interval (CI) 4.3-13.2%]. Using an immunosuppression-adjusted threshold (≥5 mm), prevalence was 23.3% (34/146; 95% CI 17.8-29.4%). The frequency of 0 mm TST induration was high (76.7%; 112/146). According to univariate analysis, LTBI positivity was linked to higher C-reactive protein (CRP), diabetes, fasting glucose ≥100 mg/dL, current smoking, smoking index >200, and urban residency. In multivariable logistic regression (outcome defined as ≥5 mm), smoking index >200 [adjusted odds ratio (OR) 11.47; 95% CI 1.52-86.6; p=0.018] and higher CRP (adjusted OR 1.036 per mg/L; 95% CI 1.006-1.070; p=0.018) remained independently associated with LTBI.

Among RA patients on csDMARDs in a north Indian tertiary center, LTBI prevalence ranged from 8.2% (≥10 mm) to 23.3% (≥5 mm). Application of the ≥5 mm TST threshold substantially increased the estimated LTBI prevalence. The high proportion of participants with 0 mm TST induration suggests reduced TST responsiveness in this population. Further studies incorporating interferon-γ release assays are needed to determine the optimal LTBI screening strategy in patients with rheumatoid arthritis receiving csDMARD therapy.

Ethics Approval

Approved by the Institutional Ethics Committee, Indira Gandhi Medical College, Shimla (IGMC/IEC/2023-142; 10 May 2023).

References

  1. World Health Organization. Global tuberculosis report 2023. Available from: https://iris.who.int/handle/10665/373828
  2. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med 2015;372:2127-35.
  3. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
  4. Flynn JL, Chan J. Tuberculosis: latency and reactivation. Infect Immun 2001;69:4195-201.
  5. Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers 2018;4:18001.
  6. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
  7. Cantini F, Nannini C, Niccoli L, et al. Risk of Tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics. Mediators Inflamm 2017;2017:8909834.
  8. Tamborenea MN, Tate G, Mysler E, et al. Prevalence of positive ppd in a cohort of rheumatoid arthritis patients. Rheumatol Int 2010;30:613-6.
  9. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999;159:15-21.
  10. Malaviya AN, Aggarwal VK, Rawat R, et al. Screening for latent tuberculosis infection among patients with rheumatoid arthritis in the era of biologics and targeted synthetic disease-modifying anti-rheumatic drugs in India, a high-burden TB country: The importance of Mantoux and Quantiferon-TB Gold tests. Int J Rheum Dis 2018;21:1563-71.
  11. Von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-9.
  12. Garziera G, Morsch ALB, Otesbelgue F, et al. Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents. Clin Rheumatol 2017;36:1891-6.
  13. Agarwal S, Das SK, Agarwal GG, Srivastava R. Steroids decrease prevalence of positive tuberculin skin test in rheumatoid arthritis: implications on anti-TNF therapies. Interdiscip Perspect Infect Dis 2014;2014:430134.
  14. Arcavi L, Benowitz NL. Cigarette Smoking and Infection. Arch Intern Med 2004;164:2206.
  15. Harries AD, Kumar AMV, Satyanarayana S, et al. Diabetes mellitus and tuberculosis: programmatic management issues. Int J Tuberc Lung Dis 2015;19:879-86.

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.